Clinical Trial

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
Trial Details
NCT Number NCT06864026
Lead Sponsor Eli Lilly and Company
Conditions Psoriatic Arthritis, Overweight or Obesity
Enrollment 200 participants
Start Date 2025-03-06
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-11